{"id":"ethaverine","rwe":[{"pmid":"38751642","year":"2024","title":"Ethaverine and Papaverine Target Cyclin-Dependent Kinase 5 and Inhibit Lung Cancer Cell Proliferation and Migration.","finding":"","journal":"ACS pharmacology & translational science","studyType":"Clinical Study"},{"pmid":"38559166","year":"2024","title":"CSF proteomic profiling with amyloid/tau positivity identifies distinctive sex-different alteration of multiple proteins involved in Alzheimer's disease.","finding":"","journal":"medRxiv : the preprint server for health sciences","studyType":"Clinical Study"},{"pmid":"37918035","year":"2023","title":"Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors.","finding":"","journal":"European journal of medicinal chemistry","studyType":"Clinical Study"},{"pmid":"36386482","year":"2022","title":"Discovery of novel inhibitors of ghrelin O-acyltransferase enzyme: an in-silico approach.","finding":"","journal":"Research in pharmaceutical sciences","studyType":"Clinical Study"},{"pmid":"32821505","year":"2020","title":"Apigenin and Ethaverine Hydrochloride Enhance Retinal Vascular Barrier In Vitro and In Vivo.","finding":"","journal":"Translational vision science & technology","studyType":"Clinical Study"}],"tags":[{"label":"ethaverine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Cerebral ischemia","category":"indication"},{"label":"Peripheral vascular disease","category":"indication"},{"label":"Parasympatholytics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{"contraindications":["Complete Atrioventricular Dissociation","Complete atrioventricular block","Glaucoma","Heart block"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"barbonin","offLabel":[],"synonyms":["ethquinol","ethaverine","barbonin","barbonine","dyscural","ethylpapaverine","ethaverine hydrochloride","ethaverine HCl"],"timeline":[],"approvals":[],"brandName":"Barbonin","ecosystem":[{"indication":"Cerebral ischemia","otherDrugs":[{"name":"papaverine","slug":"papaverine","company":""},{"name":"pentobarbital","slug":"pentobarbital","company":"Oak Pharms"},{"name":"phentolamine","slug":"phentolamine","company":"Novartis"}],"globalPrevalence":null},{"indication":"Peripheral vascular disease","otherDrugs":[{"name":"papaverine","slug":"papaverine","company":""},{"name":"pentoxifylline","slug":"pentoxifylline","company":""},{"name":"phentolamine","slug":"phentolamine","company":"Novartis"},{"name":"ticagrelor","slug":"ticagrelor","company":"Astrazeneca Lp"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"ethaverine","explanation":"Think of it like a traffic cop directing traffic in a busy city. Barbonin helps to improve blood flow by relaxing the muscles in the blood vessels, allowing more blood to reach the areas that need it. This can help to reduce the damage caused by lack of blood flow, such as in cerebral ischemia or peripheral vascular disease.","oneSentence":"Barbonin works by improving blood flow to the affected areas of the body.","technicalDetail":"Barbonin is a vasodilator that acts on the smooth muscle of blood vessels to increase blood flow, likely through a mechanism involving the inhibition of calcium channels and the activation of potassium channels."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1077","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ETHAVERINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:06:59.190273","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:51:41.061777+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"ethaverine","indications":{"approved":[{"name":"Cerebral ischemia","source":"DrugCentral","snomedId":287731003,"regulator":"FDA"},{"name":"Peripheral vascular disease","source":"DrugCentral","snomedId":400047006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000147839","MMSL":"2473","NDDF":"000697","UNII":"2H2HC19DYZ","VUID":"4019748","CHEBI":"CHEBI:94592","VANDF":"4018894","INN_ID":"299","RXNORM":"235229","UMLSCUI":"C0059703","ChEMBL_ID":"CHEMBL1555736","KEGG_DRUG":"D07926","PUBCHEM_CID":"3280","SNOMEDCT_US":"49451008","SECONDARY_CAS_RN":"985-13-7","MESH_SUPPLEMENTAL_RECORD_UI":"C007639"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":37,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"recentPublications":[{"date":"2024 May 10","pmid":"38751642","title":"Ethaverine and Papaverine Target Cyclin-Dependent Kinase 5 and Inhibit Lung Cancer Cell Proliferation and Migration.","journal":"ACS pharmacology & translational science"},{"date":"2024 Mar 16","pmid":"38559166","title":"CSF proteomic profiling with amyloid/tau positivity identifies distinctive sex-different alteration of multiple proteins involved in Alzheimer's disease.","journal":"medRxiv : the preprint server for health sciences"},{"date":"2023 Dec 15","pmid":"37918035","title":"Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors.","journal":"European journal of medicinal chemistry"},{"date":"2022 Oct","pmid":"36386482","title":"Discovery of novel inhibitors of ghrelin O-acyltransferase enzyme: an in-silico approach.","journal":"Research in pharmaceutical sciences"},{"date":"2020 May","pmid":"32821505","title":"Apigenin and Ethaverine Hydrochloride Enhance Retinal Vascular Barrier In Vitro and In Vivo.","journal":"Translational vision science & technology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Barbonin, also known as ethaverine, is a small molecule drug in the ethaverine class. It is used to treat cerebral ischemia and peripheral vascular disease. The commercial status of Barbonin is currently unknown, and it is not clear if it is patented or available as a generic. Further information on its pharmacokinetics and safety profile is also lacking. As a result, its use should be approached with caution and further research.","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:51:41.061777+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}